The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
MicroRNA-101 Inhibited Postinfarct Cardiac Fibrosis and Improved Left Ventricular Compliance via the FBJ Osteosarcoma Oncogene/Transforming Growth Factor-β1 Pathway
Open accessAbstract
Background—: Cardiac interstitial fibrosis is a major cause of the deteriorated performance of the heart in patients with chronic myocardial infarction. MicroRNAs (miRs) have recently been proven to be a novel class of regulators of cardiovascular diseases, including those associated with cardiac fibrosis. This study aimed to explore the role of miR-101 in cardiac fibrosis and the underlying mechanisms. Methods and Results—: Four weeks after coronary artery ligation of rats, the expression of miR-101a and miR-101b (miR-101a/b) in the peri-infarct area was decreased. Treatment of cultured rat neonatal cardiac fibroblasts with angiotensin II also suppressed the expression of miR-101a/b. Forced expression of miR-101a/b suppressed the proliferation and collagen production in rat neonatal cardiac fibroblasts, as revealed by cell counting, MTT assay, and quantitative reverse transcription–polymerase chain reaction. The effect was abrogated by cotransfection with AMO-101a/b, the antisense inhibitors of miR-101a/b. c-Fos was found to be a target of miR-101a because overexpression of miR-101a decreased the protein and mRNA levels of c-Fos and its downstream protein transforming growth factor-β1. Silencing c-Fos by siRNA mimicked the antifibrotic action of miR-101a, whereas forced expression of c-Fos protein canceled the effect of miR-101a in cultured cardiac fibroblasts. Strikingly, echocardiography and hemodynamic measurements indicated remarkable improvement of the cardiac performance 4 weeks after adenovirus-mediated overexpression of miR-101a in rats with chronic myocardial infarction. Furthermore, the interstitial fibrosis was alleviated and the expression of c-Fos and transforming growth factor-β1 was inhibited. Conclusion—: Overexpression of miR-101a can mitigate interstitial fibrosis and the deterioration of cardiac performance in postinfarct rats, indicating the therapeutic potential of miR-101a for cardiac disease associated with fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
Miranda, K. C., Huynh, T., Tay, Y., Ang, Y.-S., Tam, W.-L., Thomson, A. M., Lim, B., & Rigoutsos, I. (2006) · Cell · doi:10.1016/j.cell.2006.07.031 · Cited by 2,063
Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis
van Rooij, E., Sutherland, L. B., Thatcher, J. E., DiMaio, J. M., Naseem, R. H., Marshall, W. S., Hill, J. A., & Olson, E. N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805038105 · Cited by 1,844
Left Ventricular Remodeling After Myocardial Infarction: Pathophysiology and Therapy
Sutton, M. G. S. J., & Sharpe, N. (2000) · Circulation · doi:10.1161/01.cir.101.25.2981 · Cited by 1,824
MicroRNA-133 controls cardiac hypertrophy
Carè, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., Bang, M.-L., Segnalini, P., Gu, Y., Dalton, N. D., et al. (2007) · Nature Medicine · doi:10.1038/nm1582 · Cited by 1,776
Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA
van Rooij, E., Sutherland, L. B., Qi, X., Richardson, J. A., Hill, J., & Olson, E. N. (2007) · Science · doi:10.1126/science.1139089 · Cited by 1,657
van Rooij, E., Sutherland, L. B., Liu, N., Williams, A. H., McAnally, J., Gerard, R. D., Richardson, J. A., & Olson, E. N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608791103 · Cited by 1,507
AP-1 subunits: quarrel and harmony among siblings
Hess, J., Angel, P., & Schorpp-Kistner, M. (2004) · Journal of Cell Science · doi:10.1242/jcs.01589 · Cited by 1,302
Yang, B., Lin, H., Xiao, J., Lu, Y., Luo, X., Li, B., Zhang, Y., Xu, C., Bai, Y., Wang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1569 · Cited by 1,138
Self-citation
Cited by
TGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528
Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches
Beermann, J., Piccoli, M.-T., Viereck, J., & Thum, T. (2016) · Physiological Reviews · doi:10.1152/physrev.00041.2015 · Cited by 1,726
Frangogiannis, N. G. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa324 · Cited by 1,229
Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities
Frangogiannis, N. G. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.07.001 · Cited by 841
miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges
Zhou, S.-S., Jin, J.-P., Wang, J.-Q., Zhang, Z.-G., Freedman, J. H., Zheng, Y., & Cai, L. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2018.30 · Cited by 675
Self-citationFibroblasts in the Infarcted, Remodeling, and Failing Heart
Humeres, C., & Frangogiannis, N. G. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.02.006 · Cited by 410
Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives
Poller, W., Dimmeler, S., Heymans, S., Zeller, T., Haas, J., Karakas, M., Leistner, D.-M., Jakob, P., Nakagawa, S., Blankenberg, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx165 · Cited by 408
Inhibition of MicroRNA-92a Protects Against Ischemia/Reperfusion Injury in a Large-Animal Model
Hinkel, R., Penzkofer, D., Zühlke, S., Fischer, A., Husada, W., Xu, Q.-F., Baloch, E., van Rooij, E., Zeiher, A. M., Kupatt, C., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.001904 · Cited by 317
Li, X., Du, N., Zhang, Q., Li, J., Chen, X., Liu, X., Hu, Y., Qin, W., Shen, N., Xu, C., et al. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.430 · Cited by 315
Self-citationScioli, M. G., Storti, G., D’Amico, F., Rodríguez Guzmán, R., Centofanti, F., Doldo, E., Céspedes Miranda, E. M., & Orlandi, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061995 · Cited by 281
Tang, C.-M., Zhang, M., Huang, L., Hu, Z.-Q., Zhu, J.-N., Xiao, Z., Zhang, Z., Lin, Q.-X., Zheng, X.-L., -Yang, M., et al. (2017) · Scientific Reports · doi:10.1038/srep40342 · Cited by 277
Cell type–specific microRNA therapies for myocardial infarction
Liu, B., Wang, B., Zhang, X., Lock, R., Nash, T., & Vunjak-Novakovic, G. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd0914 · Cited by 53
Metadata
- Authors
- Pan, Z., Sun, X., Shan, H., Wang, N., Wang, J., Ren, J., Feng, S., Xie, L., Lu, C., Yuan, Y., Zhang, Y., Wang, Y., Lu, Y., & Yang, B.
- Venue
- Circulation
- Published
- 2012-08-14
- Volume
- 126
- Issue
- 7
- Pages
- 840-850
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2023560350
- Cited by
- 312
- References
- 37
- FWCI
- 16.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.